AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies

Amgen (AMGN) and AstraZeneca (AZN) reported positive results from a late-stage trial of their combined drug treatment for extensive-stage small-cell lung cancer. The combination of Amgen's Imdelltra and AstraZeneca's Imfinzi showed improved survival rates and response rates compared to Imfinzi alone. Imdelltra generated $513 million in sales for Amgen last year, accounting for 23% of its total revenue.

AstraZeneca's monoclonal antibody tozorakimab reduced COPD symptoms by over 30% in trials, according to the company. It aims for FDA approval in early 2024. COPD affects 16 million Americans, often linked to smoking and workplace exposures.

AstraZeneca's tozorakimab showed significant COPD exacerbation reductions in all patient groups, positioning it as a first-in-class biologic. The FDA granted priority review, and peak sales are projected to exceed $5 billion, addressing a large unmet need and supporting long-term growth.

AstraZeneca's tozorakimab showed promise in reducing COPD symptoms in late-stage trials, with 29-34% fewer exacerbations vs. placebo. The drug, a first-in-class monoclonal antibody, was accepted for FDA priority review. COPD affects 16M U.S. adults, per the CDC.

AstraZeneca's drug tozorakimab showed promise in reducing COPD symptoms in trials, including for patients with lower eosinophil counts. The drug, a monoclonal antibody, demonstrated a 29-34% reduction in exacerbations. AstraZeneca seeks FDA approval via priority review. COPD affects 16M U.S. adults, with no cure. (Source: AstraZeneca, CDC)

AstraZeneca's shares fell 0.7% to $161.51 despite positive trial results for Imfinzi in lung cancer treatment. The drug, combined with Amgen's Imdelltra, met survival goals but lacks numerical data for investor assessment. AstraZeneca provided Imfinzi and partial funding for the study.